Skip to main content

Table 2 Patients’ treatments and follow-up

From: The prognostic value of 18F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients

Clinical Characteristics

 

Patients

Neoadjuvant chemotherapy

Yes

35 (92.1%)

No

3 (7.9%)

Surgery

Yes

38 (100%)

No

0 (0%)

Post-operative chemotherapy

Yes

37 (97.4%)

No

1 (2.6%)

Endpoint events

Dead

2 (5.3%)

Recurrence or progression

17 (44.7%)

Disease free

19 (50.0%)